Every Form 4 that Metagenomi Therapeutics, Inc (MGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGX filings page.
Metagenomi Therapeutics, Inc. (MGX) reported that officer Matthew Wein, the company’s General Counsel, Compliance Officer and Corporate Secretary, had 358 shares of common stock sold on September 8, 2026 at $1.1584 per share. The shares were automatically sold to satisfy tax withholding obligations upon vesting of restricted stock units and are stated not to be a volitional trade. Following this transaction, Wein held 126,133 shares of Metagenomi common stock directly.
Metagenomi Therapeutics, Inc. (MGX) reported that President and Chief Executive Officer and director Jian Irish sold 2,140 shares of common stock on September 8, 2026 at $1.1584 per share. After this sale, she held 375,393 shares of common stock directly.
According to the filing, these shares were automatically sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025, and the transaction "does not represent a volitional trade" by Jian Irish. The filing also notes additional indirect holdings of common stock in two 2023 irrevocable trusts, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Metagenomi Therapeutics, Inc. (MGX) reported that its Chief Financial Officer, Pamela Wapnick, had 1,911 shares of common stock sold on September 8, 2026 at $1.1584 per share. The company states these shares were automatically sold to satisfy tax withholding obligations upon vesting of restricted stock units and do not represent a volitional trade. Following this transaction, Wapnick directly holds 206,580 shares of common stock.
Metagenomi Therapeutics director Reid Laurence received a grant of stock options covering 17,400 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They vest on the earlier of one year from the grant date or the company’s 2027 annual stockholder meeting, subject to his continued service.
Metagenomi Therapeutics director Dere Willard H received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. These options vest in full on the earlier of one year after the grant date or the company’s 2027 annual stockholder meeting, provided he continues serving the company through that vesting date.
Metagenomi Therapeutics director Eric Bjerkholt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and give the right to buy 21,000 shares once vested.
The options vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date. Following this grant, his reported holdings of this option award total 21,000 derivative securities.
Metagenomi Therapeutics, Inc. director Juergen Eckhardt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company's 2027 annual meeting of stockholders, subject to his continued service with the company. After this award, he holds 21,000 stock options directly.
Metagenomi Therapeutics, Inc. reported that Chief Financial Officer Pamela Wapnick had 2,884 shares of common stock sold at $1.299 per share. According to the footnote, these shares were automatically sold to cover tax withholding on vested restricted stock units and were not a discretionary trade. Following the transaction, she directly holds 208,491 shares.
Metagenomi Therapeutics director and officer Jian Irish reported an automatic share sale tied to tax withholding. On June 5, 2026, 3,737 shares of Metagenomi Therapeutics, Inc. common stock were sold at $1.299 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing states this was not a voluntary trade. After the sale, she holds 377,533 shares of common stock directly, and additional shares are held indirectly through family trusts for which she reports but disclaims full beneficial ownership. A footnote also notes that her holdings include 1,500 shares acquired under the company’s employee stock purchase plan on May 29, 2026.
Metagenomi Therapeutics, Inc. officer Matthew Wein reported an automatic sale of 558 shares of common stock at $1.299 per share on June 5, 2026. The shares were sold solely to satisfy tax withholding obligations triggered by the vesting of restricted stock units and were not a voluntary trade.
After this transaction, Wein directly held 126,491 common shares, which includes 1,500 shares acquired through the company’s employee stock purchase plan on May 29, 2026.
Metagenomi Therapeutics director and officer Jian Irish reported equity awards and updated holdings. She received a stock option covering 276,000 shares of common stock at an exercise price of $1.34 per share, expiring on March 31, 2036, with 25% vesting on April 1, 2027 and the rest in 36 monthly installments. She also received 46,000 restricted stock units, 25% of which vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments. Following these awards, she holds 379,770 shares of common stock directly, and additional shares are held indirectly by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and the Jian Irish 2023 Irrevocable Trust, where she disclaims beneficial ownership except to the extent of her pecuniary interest.
Wein Matthew reported acquisition or exercise transactions in this Form 4 filing.
Metagenomi Therapeutics officer Matthew Wein received new equity awards. On April 1, 2026, he was granted options to buy 68,000 shares of common stock at $1.34 per share, expiring on March 31, 2036. The option vests 25% on April 1, 2027, with the rest in 36 equal monthly installments, contingent on continued service. He was also granted 11,000 restricted stock units that begin vesting 25% on June 5, 2027, then in 12 equal quarterly installments. Following these compensation-related grants, his direct common stock holdings total 125,549 shares.
Metagenomi Therapeutics Chief Financial Officer Pamela Wapnick reported new equity awards. She received a grant of 144,000 stock options with an exercise price of $1.34 per share, expiring on March 31, 2036. These options relate to 144,000 shares of common stock.
She was also granted 24,000 shares of common stock in the form of restricted stock units. Twenty-five percent of the RSUs vest on June 5, 2027, with the rest vesting in 12 equal quarterly installments. Her directly owned common stock holdings total 211,375 shares after these grants. The option award vests 25% on April 1, 2027, with the remainder vesting in 36 equal monthly installments.
Metagenomi Therapeutics, Inc. Chief Financial Officer Pamela Wapnick reported an automatic sale of common stock related to tax withholding. On this transaction date, 1,581 shares of common stock were sold at $1.60 per share. According to the footnote, the shares were automatically sold to satisfy her tax withholding obligations upon the vesting of restricted stock units granted on April 1, 2024, and the transaction did not represent a voluntary trade. After this sale, Wapnick beneficially owned 187,375 shares of common stock directly.
Metagenomi Therapeutics, Inc. officer Matthew Wein reported an automatic sale of common stock related to equity compensation. On March 5, 2026, 482 shares of common stock were sold at $1.60 per share to satisfy tax withholding obligations upon the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing notes this was not a volitional trade by the reporting person. Following this transaction, Wein beneficially owned 114,549 shares of Metagenomi Therapeutics common stock.
Metagenomi Therapeutics Chief Executive Officer Jian Irish reported both a tax-related share sale and large gifts of stock. On December 5, 2025, she transferred 114,231 shares to the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and 114,231 shares to the Jian Irish 2023 Irrevocable Trust as bona fide gifts for no consideration. These trusts now hold shares for which she disclaims beneficial ownership except for any pecuniary interest. On March 5, 2026, 1,607 shares of common stock were automatically sold at $1.60 per share to satisfy tax withholding obligations from restricted stock units that vested on April 1, 2024, leaving her with 333,770 shares held directly.